Breaking India News Today | In-Depth Reports & Analysis – IndiaNewsWeekBreaking India News Today | In-Depth Reports & Analysis – IndiaNewsWeek
  • Home
  • Nation
  • Politics
  • Economy
  • Sports
  • Entertainment
  • International
  • Technology
  • Auto News
Reading: Sagility India: Strong Buy Recommendation from Brokers for Optimal Investment
Share
Breaking India News Today | In-Depth Reports & Analysis – IndiaNewsWeekBreaking India News Today | In-Depth Reports & Analysis – IndiaNewsWeek
  • Home
  • Nation
  • Politics
  • Economy
  • Sports
  • Entertainment
  • International
  • Technology
  • Auto News
© 2024 All Rights Reserved | Powered by India News Week
Trending Now: Stay updated with the latest breaking news from India and around the world
Broker’s call: Sagility India (Buy)
Breaking India News Today | In-Depth Reports & Analysis – IndiaNewsWeek > Economy > Sagility India: Strong Buy Recommendation from Brokers for Optimal Investment
Economy

Sagility India: Strong Buy Recommendation from Brokers for Optimal Investment

Economy Desk By Economy Desk September 18, 2025 2 Min Read
Share
SHARE

Target: ₹60
CMP: ₹46.48

Sagility India, a healthcare-focused Business Process Management (BPM) and digital transformation company, boasts over 25 years of experience, servicing 77 active clients that include prominent U.S. payers, providers, pharmacy benefit managers (PBMs), and technology platforms.

In the first quarter of FY26, Sagility onboarded four new clients, which include a $12 billion regional Blues plan, a $5 billion specialty health system, a pharmacy benefit manager, and a technology Third-Party Administrator (TPA) firm. The company also expanded its business with 18 existing clients, maintaining long-term partnerships that span 10 to 25 years. New business and expansion won during this period amounted to a potential steady state Annual Contract Value (ACV) of $32 million.

Sagility is making significant investments in artificial intelligence and automation, currently deploying 18 live AI use cases such as Nurse Assist, Appeals Assist, and Contract Validation, with an additional 15 use cases in development. The company has enhanced its capabilities through acquisitions of BroadPath, BirchAI, and DCI.

We assign a Buy rating to Sagility with a target price of ₹60, based on a 26× price-to-earnings (P/E) multiple on estimated earnings per share (EPS) for FY27. This assessment underscores the company’s extensive healthcare domain expertise, long-standing client relationships, improving profitability, robust cash generation, and a strategic emphasis on AI-led transformation—factors that collectively support the prospect of sustained growth and shareholder value creation.

However, Sagility’s key risks include high client concentration, potential changes in U.S. healthcare regulations, elevated employee attrition, currency fluctuations, and a goodwill-heavy balance sheet resulting from acquisitions, all of which may impact growth and profitability.

Published on September 18, 2025.

TAGGED:Economy NewsNews
Share This Article
Twitter Copy Link
Previous Article Broker’s call: Aadhar Housing (Buy) Invest in Aadhar Housing: A Strong Buy Recommendation
Next Article Mushfiqur Rahim set to become first Bangladesh cricketer to play 100 Tests in November Mushfiqur Rahim Poised to Make History as Bangladesh’s First 100-Test Cricketer in November
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Latest News

Stock Market Today Live, Nov 16: Sensex, Nifty pare early gains as investors assess sustainability of market rally

Market Update: Sensex and Nifty Trim Early Gains Amid Investor Concerns on Rally Longevity

November 16, 2026
Mahindra's electric three-wheeler arm eyes IPO in 18 months

Mahindra’s Electric Three-Wheeler Division Plans IPO Within 18 Months Amid Growing Demand

November 16, 2026
Photos: Pope Leo visits Peru’s Amazon and Andean regions during 12-day tour

Pope Leo Embarks on 12-Day Tour of Peru’s Amazon and Andean Regions

November 16, 2026
SEBI bars EKI Energy MD Manish Dabkara for 12 months over financial misrepresentation

SEBI Suspends EKI Energy’s Manish Dabkara for 12 Months Due to Financial Misrepresentation

November 1, 2026
A cure for Trump? Why Democratic doctors are running in the 2026 midterms

Democratic Doctors Aim to Counter Trump Influence in 2026 Midterms

November 1, 2026
Tech Query: ICICI Prudential Asset Management Company (AMC), Latent View Analytics, Rashtriya Chemicals and Fertilizers, IRB Infrastructure Developers — What is the outlook? Where are these stocks headed? 

Market Outlook: Future Prospects for Sundram Fasteners, HDB Financial, Sterlite Tech, and Techno Electric

October 31, 2026

You Might Also Like

Baroda BNP Paribas MF targets ₹98,000 crore AUM in 3 years
Economy

Baroda BNP Paribas MF aims for ₹98,000 crore AUM in 3 years.

2 Min Read
Stock Market Today Live, Sept 25: Sensex, Nifty hold marginal gains at noon amid global headwinds
Economy

Sensex and Nifty Steady at Noon Gains Despite Global Challenges – Stock Market Update, Sept 25

6 Min Read
Hindustan Unilever shares down 2.7% on sales impact forecast
Economy

Hindustan Unilever Stock Drops 2.7% Amid Sales Impact Concerns

1 Min Read
Lotus Emira review: The right Lotus
Economy

Emira: Lotus’s Unique Title

2 Min Read

About IndiaNewsWeek

IndiaNewsWeek is your trusted source for breaking news, in-depth analysis, and comprehensive coverage of India and the world. We deliver accurate, timely reporting across politics, economy, sports, entertainment, and technology.

contact@indianewsweek.com

Quick Links

  • Nation
  • Politics
  • Economy
  • International
  • Sports
  • Entertainment

More Sections

  • Technology
  • Auto News
  • Education
  • About Us
  • Contact
  • Privacy Policy

Stay Connected

Follow us on social media for the latest updates and breaking news.

Facebook
X (Twitter)
YouTube
Follow US
© 2026 IndiaNewsWeek. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?